Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 455 results for anxiety

  1. Priority of treatment for people with anxiety and depression:- For people with both anxiety and depression, which disorder should be treated first to improve their outcomes?

    Question Priority of treatment for people with anxiety and depression:- For people with both anxiety and depression, which...

  2. Mental health of adults in contact with the criminal justice system (QS163)

    This quality standard covers recognising, assessing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system (this includes police contact, court and prison custody, street triage, liaison and diversion services, and probation services). It describes high-quality care in priority areas for improvement.

  3. Is chamomile/ginkgo biloba more effective than placebo in increasing response and remission rates and decreasing anxiety ratings for people with generalised anxiety disorder (GAD)?

    increasing response and remission rates and decreasing anxiety ratings for people with generalised anxiety disorder (GAD)?...

  4. Adults' uptake of and engagement with interventions for social anxiety disorder:- What methods are effective in improving uptake of and engagement with interventions for adults with social anxiety disorder?

    for social anxiety disorder:- What methods are effective in improving uptake of and engagement with interventions for adults with social...

  5. Depression and anxiety: review within 10 to 35 days (IND104)

    This indicator covers the percentage of patients with a new diagnosis of depression in the preceding 1 April to 31 March who have been reviewed within 10 to 35 days of the date of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM50

  6. Individual versus group CBT for children and young people with social anxiety disorder:- What is the clinical and cost effectiveness of individual and group CBT for children and young people with social anxiety disorder?

    social anxiety disorder:- What is the clinical and cost effectiveness of individual and group CBT for children and young people with...

  7. Pharmacological interventions for anxiety disorders in people with learning disabilities who have autism:- What is the clinical and cost effectiveness and safety of pharmacological interventions for anxiety disorders in people with learning disabilities who have autism?

    Recommendation ID NG54/4 Question Pharmacological interventions for anxiety disorders in people with learning disabilities who have...

  8. Coeliac disease: recognition, assessment and management (NG20)

    This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.

  9. The role of parents in the treatment of children and young people with social anxiety disorder:- What is the best way of involving parents in the treatment of children and young people (at different stages of development) with social anxiety disorder?

    role of parents in the treatment of children and young people with social anxiety disorder:- What is the best way of involving parents...

  10. Combined interventions for adults with social anxiety disorder:- What is the clinical and cost effectiveness of combined psychological and pharmacological interventions compared with either intervention alone in the treatment of adults with social anxiety disorder?

    CG159/5 Question Combined interventions for adults with social anxiety disorder:- What is the clinical and cost effectiveness of...

  11. Autism spectrum disorder in adults: diagnosis and management (CG142)

    This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.

  12. Digitally enabled therapies for adults with depression: early value assessment (HTE8)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....

  13. Baricitinib for treating severe alopecia areata (TA926)

    Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.

  14. Tinnitus: assessment and management (NG155)

    This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

  15. Faltering growth: recognition and management of faltering growth in children (NG75)

    This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.